BioSpace News Archive

Castellum, Inc. (ONOV: OTC) today provides the following Corporate letter updating its shareholders:

Aceto, a leading global virtual manufacturer of specialty materials for life sciences and advanced technology end markets, announced the introduction of an expanded portfolio for biopharmaceutical and cell culture reagent manufacturers.

Today, ImmunaBand—the first-to-market wearable COVID-19 vaccination documentation to signify an individual’s vaccination status—announced their public launch.

- SpectronRx is a well-established CDMO with a reputation of supplying high-quality, GMP/Pharmaceutical grade isotopes without impurities that meet FDA standards for radiopharmaceuticals - - Building out VMT-

In light of the ongoing COVID-19 situation, the Company strongly encourages registered shareholders and proxyholders not to attend the AGM in person, and Shareholders are encouraged to vote using one of the methods described in the Management Information Circular (“MIC”) which can be viewed on SEDAR.

Relay is a founding shareholder of Glow and recently added to its position by participating in Glow’s RTO financing on February 9, 2021, which was oversubscribed at over $5.1 million raised.

HTX Urology in Webster, TX (www.htxurology.com) is participating in an FDA cleared research study for a new, minimally invasive device pioneered by Urotronic, Inc., that could dramatically change the way millions of men with enlarged prostates are treated.

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “Company”), a technology company providing comprehensive testing solutions through its scalable platform, today announced that the U.S. Centers for Disease Control and Prevention (“CDC”) has awarded the Company a contract to provide genomic sequencing of samples of SARS-CoV-2 on an ongoing basis,

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced the appointment of Igor Bilinsky, Ph.D., as Chief Operating Officer, effective today. Dr. Bilinsky brings more than 20 years of biotechnology industry experience as a senior executive and consultant, including public companies.

Total second quarter revenue of $31.5 million increased 62% year-over-year on continued recovery and expansion from impact of COVID-19 pandemic Second quarter clinical laboratory revenue of $24.0 million increased 92% on significant volume and pricing growth due to improved product mix Consolidated quarterly gross margin of 50% improved 2000 basis points year-over-year